Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy

Cardiovascular (CV) risk mitigation is an important consideration in the management of chronic myeloid leukemia (CML) patients. Although BCR-ABL1 inhibition by tyrosine kinase inhibitors (TKI) has led to a significant improvement in prognosis, the majority of CML patients will require indefinite TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Nodzon, Lisa, Fadol, Anecita, Tinsley, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955565/
https://www.ncbi.nlm.nih.gov/pubmed/35369400
http://dx.doi.org/10.6004/jadpro.2022.13.2.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955565/
https://www.ncbi.nlm.nih.gov/pubmed/35369400
http://dx.doi.org/10.6004/jadpro.2022.13.2.4

Ejemplares similares